GLPwatch
A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes
NCT03315780 · Completed
Last updated 2026-05-28This clinical trial tested the effects of the medication dulaglutide on blood sugar levels in Japanese adults with type 2 diabetes.
Status Completed The study has finished.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Randomized, single-blind treatment study
Participants 12 people
Who can join Ages 20–75 · all sexes
Timeline Started 2017-10 · est. completion 2018-02
Where 1 site · Japan
What this study is testing ClinicalTrials.gov NCT03315780 ↗
Description as written by the study sponsor.
The purpose of this study is to evaluate the glucodynamic effects of dulaglutide in Japanese participants with type 2 diabetes mellitus.
Treatments tested
- Dulaglutide also known as LY2189265 Drug
Administered SC
- Placebo Drug
Administered SC
| Main thing measured | Change From Baseline in Glucose Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC[0-4h]) |
|---|---|
| Sponsor | Eli Lilly and Company |
| Conditions studied | Type 2 Diabetes |
| GLP-1 drugs | dulaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03315780 ↗